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Background: Pharmacist interventions are one of the pivotal parts of a clinical pharmacy service within a hospital.
This study estimates the cost avoidance generated by pharmacist interventions due to the prevention of adverse
drug events (ADE). The types of interventions identified are also analysed.
Methods: Interventions recorded by a team of hospital pharmacists over a one year time period were included in
the study. Interventions were assigned a rating score, determined by the probability that an ADE would have
occurred in the absence of an intervention. These scores were then used to calculate cost avoidance. Net cost
benefit and cost benefit ratio were the primary outcomes. Categories of interventions were also analysed.
Results: A total cost avoidance of €708,221 was generated. Input costs were calculated at €81,942. This resulted in
a net cost benefit of €626,279 and a cost benefit ratio of 8.64: 1. The most common type of intervention was the
identification of medication omissions, followed by dosage adjustments and requests to review therapies.
Conclusion: This study provides further evidence that pharmacist interventions provide substantial cost avoidance
to the healthcare payer. There is a serious issue of patient’s regular medication being omitted on transfer to an
inpatient setting in Irish hospitals.
Keywords: Hospital pharmacy, Adverse drug events, Health care economics, Ireland, Clinical pharmacy services,
Cost avoidanceBackground
The traditional role of a pharmacist predominantly in-
volved the dispensing of medications in both hospital
and community settings; consequently the pharmacist
was quite detached from other healthcare professionals.
The profession has since evolved to become recognised
as an essential part of the healthcare team [1]. While still
ensuring that medicines are sourced and dispensed to
the highest possible standards, pharmacists have diversified
into alternative areas of care in hospital practice [2]. Inter-
ventions are integral components of the new enhanced role
which pharmacists offer in a clinical setting [3-8].
A pharmacist intervention is defined as any action taken
by a pharmacist that aims to change patient management
or therapy [9]. A pharmacist’s expertise in pharmacology,
pharmacotherapy and pharmaceutics ensures they have the* Correspondence: j.e.gallagher@umail.ucc.ie
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unless otherwise stated.requisite capabilities to offer suggestions to other healthcare
staff on possible alterations to a patient’s therapy [10,11].
This helps to ensure optimal patient outcomes, which has
the potential to have an add-on economic benefit to the
healthcare institution.
A myriad of studies have described the high rate of po-
tential inappropriate prescribing and potential adverse
drug events (ADE) in multiple healthcare systems [12-16].
An ADE is defined by the International Conference for
Harmonisation as “any untoward medical occurrence in a
patient administered a medicinal product which does not
necessarily have to have a causal relationship with treat-
ment”. These issues cause repercussions in the form of in-
creased resource utilisation [17]. Evidence of the clinical
benefit and reduction in ADEs associated with enhanced
roles for pharmacists in a hospital setting, are documented
in the literature [2,5,18,19].
Healthcare systems worldwide are coming under in-
creasing pressure due to a combination of aging popula-
tions and the proliferation of new expensive technologiesral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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value for money for the investment made in their provision
[21]. Despite early scepticism, health economic evaluations
are required for the establishment and continued provision
of services and technologies [20].
The provision of a clinical pharmacy service in a hos-
pital setting is an investment which utilises costs which
could be used elsewhere in the health system. Economic
evaluations of clinical pharmacy services will help policy
makers make informed decisions on whether they are a
worthwhile investment. Studies in other jurisdictions
have indicated that they are cost-effective, however these
findings are not generalisable [22,23].
This paper will analyse the interventions made by a
team of pharmacists in a university teaching hospital
and evaluate the cost avoidance achieved through the
prevention of an ADE. For the purposes of this study,
cost avoidance refers to an intervention that reduces or
eliminates additional expenditure that otherwise may have
been incurred in the absence of the intervention [24]. It is
a different measure to cost saving interventions, which
refer to reductions in current spending due to changes in
the expenditure on a patients treatment [25]. Cost avoid-
ance interventions contain and control costs and over a
longer period of time they can result in cost savings.
The study was based in an Irish university teaching
hospital/tertiary referral centre setting over a period of
one year. Similar studies have been performed, examining
shorter time periods or focusing on specific interventions
[3-7,25]. However, information which helps to evaluate
the economic impact of pharmacist interventions over
a longer period of time and covering an entire hospital
domain is lacking. The authors have been unable to
find a study where cost avoidance generated by a full
department of clinical pharmacists in a full calendar year
has been calculated.
Methods
Setting
This was a retrospective study based on a 1 year time
period from 01/01/2012 to 31/12/2012 inclusive. Cork
University Hospital (CUH) and the Cork University
Maternity Hospital is a combined 850-bed hospital site.
The hospital serves a population of over 620,000. In
addition, it is a tertiary referral centre for over 1 million
people, in the southern region of the Republic of Ireland.
Approximately 32,000 inpatient admissions were recorded
for 2012. All patients who were in receipt of a pharmacist
intervention on their drug therapy were included in
this study. There were no additional exclusion criteria.
The Pharmacy Department consists of 15.8 whole time
equivalent (WTE) pharmacists. As two WTEs are
employed in managerial and administrative capacities,
13.8 WTE are available to document interventions aspart of the daily pharmaceutical service. Interventions
performed in all areas of the hospital, including the
maternity unit, were included in this study.
Intervention analysis
Clinical pharmacist interventions are provided by many
basic and senior grade pharmacists at CUH. Clinical
pharmacist interventions are carried out at patient admis-
sion, during pharmacist led patient chart review or at the
request of another healthcare professional. As previously
discussed, the primary goal of a clinical pharmacist inter-
vention is to ameliorate patient therapy.
Interventions made by pharmacists were recorded on
a duplicate paper form. One form is kept by the pharma-
cist and one is passed on to the attending physician who
has the final decision on whether to accept or reject the
intervention.
In addition to producing a paper record of the inter-
vention, the pharmacist retrospectively enters the pro-
posed intervention into the ‘eClinical Pharmacy Suite’.
The ‘eClinical Pharmacy Suite’ is a browser-based applica-
tion, aimed at supporting clinical pharmacists to record,
grade and report medication related interventions or errors.
Interventions were assigned by the clinical pharmacist
to the most appropriate category in the application. Due
to time constraints, not all recorded intervention had
been entered on the computerised database. The primary
researcher inputted any outstanding interventions and veri-
fied data which had been previously entered by hospital
pharmacists. Intervention categories were developed based
on the recommendations of an advisory group of clinical
pharmacists from Ireland.
Cost analysis
The cost of providing this service was calculated based
on the average time it took to carry out an intervention
and the hourly cost of employing a hospital pharmacist.
The average time of an intervention was based on a pre-
viously published study, which showed that the majority
of pharmacist interventions in a university hospital setting
took between 15 – 30 minutes to complete [7]. The hourly
rate of employing a pharmacist at the mid-point of the
salary scale was calculated based on an annual salary of
€49,425 (Point 6 of 2010 salary scale) [26]. This under-
went upward revision to account for employer related
costs and hospital overheads based on guidance for con-
ducting an economic analysis within the Irish healthcare
system [27-29]. Base case scenario was calculated using
the hourly cost of employing a basic level pharmacist at
the mid-point of the salary scale and an average inter-
vention time of 22.5 minutes.
Cost avoidance was calculated based on the probability
that an ADE would have occurred in the absence of the
proposed pharmacist intervention [18]. Interventions were
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based on the probability of a patient experiencing harm
directly or indirectly from their prescribed/administered
medicines, and also the potential of omission of regular
medication, sub-therapeutic dosing or an ill-advised choice
of therapy. Determination of the probability that a patient
would experience harm in the absence of an action by
a pharmacist was based on the methodology described
by Nesbit et al. [25] (Table 1). The cost avoidance for each
individual intervention was determined and total cost
avoidance was accordingly calculated through summation
of the individual interventions. A random sample of the
interventions (n = 100) were reviewed by two academic
pharmacists with hospital pharmacy experience and
inter-rater reliability was calculated for the sample.
The authors were unable to find an estimated cost of
an ADE, calculated based on data from the Irish healthcare
system. The additional cost of treating an inpatient that
experienced an ADE was taken from a recent study which
utilised a micro-costing approach based on data from
German hospitals [30]. This study also included a range
of previously published ADE estimates (€934 – 5783).
The majority of previously published studies which cal-
culate cost avoidance used a cost of ADE determined by
Bates et al. [5,7,24,25]. Rottenkolber ADE valuation was
deemed to be more appropriate for this study as it was
published in 2012 while Bates study was published in
1997 using US data [31]. This removed the need to account
for currency differentials and inflation. Purchasing power
parities between Germany and Ireland were used to further
minimise differentials between the two countries. Cost of
an ADE used in base case scenario was €1057.
A micro-costing approach, assigns a valuation to each
individual unit of resource consumed and is considered
the most robust costing method [32]. Diagnosis related
group (DRG) costs for toxic side effects of drugs based
on Irish hospital data were available but were not chosen
as the cost of an ADE. The DRG estimate exclusivelyTable 1 Nesbit method for calculating indirect cost benefit [2
Equation 1: Cost avoidance
for individual intervention
Pro
Probability of an ADE occurring Probability score
No harm expected 0.00
Very low 0.01
Low 0.10
Medium 0.40
High 0.60
Source Nesbit, T.W. et al.: Implementation and pharmacoeconomic analysis of a clinic
58(9), 784–790 (2001).measured toxic side effects of drugs [33], furthermore
DRG costs are generally less accurate in comparison to
micro-costing estimates [32]. DRG costs for toxic side
effects for drugs (€887) were included in sensitivity analysis
calculations.
Following estimation of the cost of carrying out the
pharmacist interventions and the resulting cost avoid-
ance, net cost benefit and cost benefit ratio for providing
the service were calculated. Analysis was calculated from
the perspective of the healthcare institution. Discounting
was excluded as events were all considered to have taken
place in a 1 year time period.
Sensitivity analysis
One way deterministic sensitivity analysis was performed.
Published ranges and confidence intervals where available
determined the extent of the parameters. Sensitivity ana-
lysis was also performed using alternative published costs
of an ADE [31], Irish DRG data and with various interven-
tion acceptance rates.
Data analysis
Reports generated from the eClinical Pharmacy Suite
database were in Microsoft ExcelTM format. Summary
statistics were calculated through Microsoft Excel 2010
(Microsoft Corp., Redmond, Washington). All other
advanced analysis was conducted through IBM SPSS
Statistics Version 18.
Ethical approval
Approval was obtained from the Clinical Research Ethics
Committee of the Cork Teaching Hospitals, University
College Cork, Ireland.
Results
A total of 4,257 interventions were documented on
2,147 individual patients (Table 2). The majority of the
interventions were judged to have prevented potential5]
bability of an ADE occurring X cost of an ADE [30]
OR (0 or 0.01 or 0.1 or 0.4 or 0.6) X €1057
Example
Pharmacist suggests changing patient from esomeprazole
to omeprazole exclusively for economic reasons.
Patient regularly takes a bisphosphonate, but medication
omitted from hospital kardex
Patient takes an antibiotic twice daily, when recommended
dose would be three times daily.
Metformin dose not reduced despite patient demonstrating
renal impairment.
Patient prescribed amiodarone while currently taking digoxin
without any reduction in digoxin dose.
al staff pharmacist practice model. American journal of health-system pharmacy
Table 2 Intervention analysis
Number of
interventions
Total number of patients who received intervention 2147 patients
Total number of interventions 4257
Mean number of interventions per patient (St. dev.) 1.98 (1.60)
Median number of interventions per patient (95% CI) 1 (0.06)
Range of interventions per patient 1 - 18
Interventions accepted by physicians (%) 1275 (29.92)
Interventions rejected by physicians (%) 61 (1.43)
Interventions with unknown acceptance outcome (%) 2921 (68.81)
Table 4 Intervention categorisation
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discernible impact on therapy or patient outcomes, based
on the judgement of the primary author. Additional inter-
ventions required entry under multiple categories on the
database, but were only evaluated once for potential
prevention of an ADE.
Recorded acceptance rate by physicians was 29.92%
(n = 1275). Only 1.43% (n = 61) interventions were re-
corded as being rejected by a physician. However, the
rate of interventions with an unknown acceptance out-
come was high, 68.81% (n = 2921).
Substantial cost avoidance of €710,000 was generated
over a 1 year period from the perspective of the health care
provider. Mean cost avoidance of €166 per intervention
was generated. The cost of providing these interventions
was €82,000. Substantial net cost benefits of €626,279 and a
cost benefit ratio of 8.64 were generated based on this
evaluation of pharmacist interventions (Table 3).
The number of interventions that potentially avoided
ADEs were as follows: 119 (2.8% of all interventions) of
the interventions were associated with a probability score
of 0.6 (high likelihood of preventing an adverse event), 1101
interventions (25.86%) were associated with a probability
score of 0.4 (medium), 1514 interventions (35.56%)Table 3 Cost analysis of pharmacist interventions
Base case
(Range)
1. Cost avoidance €708221
(625808–3874783)
2. Cost of Service
- Pharmacist Wages €81942
(22402 –110389)
a3 = (1–2) Net Cost Benefit €626279
(567173–3764394)
b4 = (1/2) Cost Benefit Ratio Net Cost BenefitCost of Service 8.64
a(Cost avoidance – Cost of Pharmacy Services).
b(Net Cost Benefit ÷ Cost of Service).were associated with a probability score of 0.1 (low),
683 interventions (16.04%) were associated with a prob-
ability score of 0.01 (very low) and 840 interventions
(19.73%) were associated with a probability score of 0
(no harm expected).
The most prevalent type of intervention was the iden-
tification of omissions of patient’s regular pre-admission
medication, followed by requests to change the dose of
medications and requests for the physician to consider
whether it was appropriate to continue with a medication
(Table 4). The most common categories of medications
to require interventions were proton pump inhibitors
(n = 259), statins (n = 208), beta-blockers (n = 165), cor-
ticosteroids (n = 161) and penicillins (n = 157).
Inter rater reliability indicated an acceptable level of
agreement, based on a random sample of 100 interven-
tions. Average agreement between 3 raters was 0.744.
Individual pairwise agreement was over the significant
level of 0.7 for all 3 comparisons: Primary Rater (PR) –
Academic Pharmacist (AP) 1 = 0.763, PR – AP 2 = 0.761,
AP 1 – AP 2 = 0.709.
In all scenarios examined, the cost-benefit ratio remained
positive (Table 5). All known variables underwent a one-
way sensitivity analysis based on known ranges or using
variations used in previously published sensitivity analysis
on the topic. Nesbit et al. conducted a sensitivity analysis
where the ADE probability underwent an each way vari-
ation of 50%, an identical variation was undertaken in this
paper [25]. The greatest variance in cost-benefit ratio was
displayed in the cost assigned to an ADE.
Two additional ADE cost estimates were investigated
during the course of sensitivity analysis (Table 6). The
estimated cost of an ADE calculated by Bates and adjusted
due to change in setting and year resulted in a considerable
increase in the cost benefit ratio.Category of intervention N (%)
Drug 2759 (64.81%)
- Drug, Omissions 1820 (65.93% of Drug Category)
- Drug, Review Therapy 421 (15.24% of Drug Category)
- Drug, Interaction 124 (4.56% of Drug Category)
- Drug, Other 394 (14.27% of Drug Category)
Doses 920 (21.61%)
Frequencies 354 (8.32%)
Routes 125 (2.94%)
Duration 47 (1.10%)
Other 27 (0.63%)
Date/Time 20 (0.47%)
Rates 5 (0.12%)
Table 5 Sensitivity analysis for cost-benefit ratios
Variable Lower limit (Cost Benefit Ratio) Upper limit (Cost Benefit Ratio)
Time 30 minutes per intervention 6.48 15 minutes per intervention 12.96
ADE Probability −50% Probability score 4.32 +50% Probability score 12.96
Salary Highest point on senior pharmacist scale 6.42 Lowest point on basic pharmacist scale 12.07
ADE CostA Lowest point on range 7.63 Highest point on range 47.28
Intervention acceptance 50% Acceptance 4.32 Known Acceptance (29.92%) 2.59
AADE range taken from a review of selected international studies regarding the economic consequences of ADEs which reported additional mean costs in the
range of €934 to €5783 per case [34].
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Substantial cost avoidance was demonstrated in this study.
Cost benefit ratio and net cost benefit remained positive
under all conditions examined. To the authors’ knowledge,
this study is the first that has attempted to estimate the
cost avoidance achieved in a total hospital environment
over such an extended period of time. Direct comparison
of savings generated in this study with previously published
studies is difficult. The generalizability of pharmacoeco-
nomic analysis is uncertain [35]. Calculation of cost avoid-
ance will have inter study variations in the cost assigned
to an ADE, methodologies, healthcare settings, duration of
study and number of pharmacists employed.
The original study which implemented the cost avoid-
ance method used in this paper generated a net benefit
of $392,660 [25]. This was over a similar 12 month period
but only included 3 WTE pharmacists operating on three
specific hospital wards. Study location was in a US hospital.
These pharmacists had undergone specialist training and
were to a large extent exclusively performing interventions
during their participation in the study. Cost benefit ratio
of 3.1:1 was considerably smaller in the Nesbit study.
Cost-benefit ratio was influenced significantly by the
method used to calculate the cost of the service. The
complete pharmacist salary was used to calculate the
cost of providing the intervention rather than appor-
tioning part of the salary based on the time pharmacist
spent enacting the interventions.
A study by Olson et al. conducted in a 360 bed US
hospital has the greatest methodological agreement with
this paper [7]. This was conducted over a 3 month period
and estimated the cost benefit ratio to be 1.2. Only 5 phar-
macists provided interventions in this study. Although,
substantial savings ($84,631) was generated from a small
number of interventions, the cost-benefit ratio was lower
than expected. As with the Nesbit study, cost-benefit ratio
was reduced as full pharmacist salary was used toTable 6 Sensitivity analysis using alternative ADE estimates
Alternative ADE estimate Cost benefit ratio
DRG Toxic Side Effects [33] 7.25
Bates ADE Costing [31] 49.49calculate the cost of providing the service. The results in
this study provides evidence that the positive cost benefit
ratio of clinical pharmacists’ interventions is maintained
over a longer period of time, with additional pharmacists
and in a wider hospital setting.
Cost avoidances are impacted significantly if they are
focused in specific departments. Cost avoidance per
intervention generated in our study was decidedly lower
in comparison to a study conducted in an intensive care
unit. The addition of a single critical care pharmacist to a
16 bed intensive care unit produced an average cost avoid-
ance of $1596.27 - $1615.67 per intervention [5]. Input
costs were omitted in this study so further comparison
was not feasible.
While the cost-benefit ratio in this study was posi-
tive, it needs to be reiterated that this ratio was based
on estimates of time and avoidance of cost rather than
hard economic data. Therefore, the ratio could poten-
tially be an overestimate. Furthermore, an evaluation
of a clinical pharmacy service is strengthened when it
also includes an assessment of the clinical and humanistic
outcomes involved [36].
This high degree of omissions of patient’s regular
pre-admission medications (43% of all interventions)
highlights the need for a dedicated system of medicines
reconciliation at a tertiary healthcare level in Ireland.
A pilot study of pharmacist-led medication reconciliation
in two university teaching hospitals, elsewhere in Ireland,
also identified omission of a pre-admission medication
as the most common discrepancy [37]. These findings
are replicated in other healthcare settings [38]. Medication
omissions can have potentially serious consequences for pa-
tients depending on the nature of the drug omitted [39].
An argument could be presented not to include medica-
tion omissions as an ADE, based on a strict interpretation
of the definition, as the patient did not receive the drug
[40]. However, the decision was taken to include them
in this study. Similar studies in the past have included
the identification of medication omissions as a potential
ADE [7,41]. The probability of a patient incurring harm
is increased if they do not receive their regular medica-
tion, resulting in a related increase in hospital resource
utilisation [42].
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probabilities assigned to the interventions. This re-
flects findings obtained in the majority of previous
studies which implemented the same method of calcu-
lating cost avoidance [5,25,41]. The frequency of these
scores were influenced by the number of medication
omissions (39% of omissions were assigned a medium
probability score and 37% assigned a low probability score.)
Interventions designated with a high probability of pre-
venting an ADE were largely composed of omissions of
essential medications (e.g. anti-epileptic drugs) or known
serious drug interactions.
The most common medication classifications requiring
intervention were unsurprising. Proton pump inhibitors
(PPI) were the medication classification requiring the
most frequent intervention. Interventions on PPIs were
largely suggestions to change to lower cost equivalents,
highlighting therapeutic duplication, excess of therapy or
suggestion for switching from intravenous to oral adminis-
tration. The majority of these interventions resulted in cost
savings to the healthcare provider. Inappropriate pre-
scribing of PPIs is a significant issue in the Irish health-
care system and a significant drain on resources [43,44].
This demonstrates the pivotal role can play as cost con-
tainers in the healthcare system.
Another method of increasing the number of interven-
tions would be the provision of further training for clinical
pharmacists which would enable them to become special-
ists in various areas of patient care. This practice is com-
mon in other countries and has been shown to provide
substantial monetary savings from interventions enacted
by specialist pharmacists [5]. Specialised anti-microbial
pharmacists have been shown to be of value and are now
established in many hospitals in Ireland [45,46].
A significant level of agreement was found between
three of the listed authors. Assignment of probabilities is
subjective; therefore a high level of agreement is unlikely.
On review of samples, almost all were within 1 score of
each other, further indicating that probabilities were
assigned by the primary author in a manner consistent
with fellow professionals. Although, inter rater reliabil-
ity was not examined for all interventions, the clinical
background of the primary rater and the significant
agreement level demonstrated in the sample indicate
the ADE probabilities were assigned in an appropriate
and consistent manner.
There was a high rate of interventions where the out-
come was unknown at time of analysis. However, review
of interventions where status was determined indicated
that only a small minority of pharmacist interventions
were rejected. This indicates that other healthcare profes-
sionals are receptive to pharmacist interventions on patient
medication. The high level of unknown outcomes was most
likely due to time constraints on the pharmacist. Followingacceptance or rejection, system requires manual updating.
It is understandable that an administrative task such as this
may be neglected.
The importance of an accurate estimation of ADE
cost was emphasized from the dramatic increase in cost
benefit ratio if Bates et al. estimate of ADE was used. As
previously stated, there is an absence of data on ADE costs
in Ireland. The validity of estimated cost avoidance would
be improved through application of local data on excess
costs associated with ADE. Until this issue has been ad-
dressed, imperfect data is the only viable option. Sensitivity
analysis undertaken in this study was deterministic in na-
ture; performing probability sensitivity analysis would have
been a more accurate robust method to determine whether
pharmacist interventions would have maintained a positive
cost benefit ratio.
The primary limitation was the limited availability of
additional patient information (medical record, medical
history, outcome of intervention etc.) when assigning
adverse drug event probabilities. As this study contained
a large number of patient interventions, it was not
feasible to retrospectively retrieve this information
from medical notes.
Another major limitation was the exclusion of some
potential input costs. In order to conduct an intervention,
problems must be located which takes up pharmacist time
and therefore has an associated cost. Screening of a pa-
tient’s medication may not be exclusively for the purpose
of discovering interventions but it is one possible outcome
from it. Additionally, other healthcare professionals are
required to spend time reviewing suggested pharmacist
interventions. This was also excluded from analysis.
Utilisation of a scoring system which also accounts
for the severity of the potential ADE would significantly
enhance this study. Such scoring systems exist but they do
not assign a cost with the scoring outcome generated.
There is no ideal system for assigning probabilities to ad-
verse events but the widespread adaptation of one system
would add to the ability to compare studies across jurisdic-
tions. The classification of interventions is subjective.
Generation of local guidelines on the classification of
interventions would help reduce this variation.
While the interventions included in the study represented
the majority of work conducted by clinical pharmacists, it
is possible that some interventions were not inputted on
to the eClinical System. Therefore, the current data may
under-represent the cost avoidance produced.
The interventions were assigned scores by an individual
rater. While sample of interventions examined for
inter-rater reliability indicated that the primary author
was assigning probability scores in a manner consistent
with other pharmacists, review of complete dataset by
additional pharmacists and other medical professionals
would have enhanced the study.
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Previous reviews have indicated that pharmacist interven-
tions generate significant cost avoidance when measured
under certain criteria and conditions [18]. This study has
confirmed previous opinions and supplemented the body
of evidence that the provision of clinical pharmacy ser-
vices in an entire hospital provides value for money to the
healthcare payer. An excessive amount of omissions of
regular medications has been highlighted by this study.
The estimation of cost avoidance would be improved by
the development of a method which incorporated the
potential severity of an ADE into the evaluation and an
evaluation of excess costs associated with ADEs in an
Irish healthcare setting.
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